News
RGEN
122.59
+2.07%
2.49
1 Cash-Producing Stock Worth Your Attention and 2 We Avoid
Barchart · 9h ago
Weekly Report: what happened at RGEN last week (0406-0410)?
Weekly Report · 1d ago
Repligen: Advancing, Yet Much More Work Ahead
Seeking Alpha · 5d ago
Repligen Price Target Cut to $140.00/Share From $170.00 by Evercore ISI Group
Dow Jones · 04/06 18:01
Evercore ISI Group Maintains Outperform on Repligen, Lowers Price Target to $140
Benzinga · 04/06 17:51
Weekly Report: what happened at RGEN last week (0330-0403)?
Weekly Report · 04/06 10:14
Reassessing Repligen (RGEN) Valuation After Recent Share Price Rebound And Bioprocessing Growth Expectations
Simply Wall St · 04/05 03:26
Repligen publishes 2025 annual report, posts $738 million revenue in 2025
Reuters · 04/03 11:20
Q/C Technologies delays annual report filing, seeks 15-day extension
Reuters · 03/31 20:35
Is Repligen (RGEN) Pricing Look Attractive After Steep Multi Year Share Price Declines
Simply Wall St · 03/31 19:07
Weekly Report: what happened at RGEN last week (0323-0327)?
Weekly Report · 03/30 10:14
RadNet, Evolent Health, Illumina, Charles River Laboratories, and Repligen Stocks Trade Down, What You Need To Know
Barchart · 03/27 13:16
Analysts Are Bullish on These Healthcare Stocks: Repligen (RGEN), Amylyx Pharmaceuticals Inc (AMLX)
TipRanks · 03/25 16:50
Repligen Price Target Raised to $208.00/Share From $180.00 by HC Wainwright & Co.
Dow Jones · 03/23 11:18
Repligen Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 03/23 11:18
HC Wainwright & Co. Maintains Buy on Repligen, Raises Price Target to $208
Benzinga · 03/23 11:08
Repligen: Strong Execution, Innovation, and Cross‑Selling Momentum Support Sustained Growth and Reaffirmed Buy Rating
TipRanks · 03/23 10:16
Weekly Report: what happened at RGEN last week (0316-0320)?
Weekly Report · 03/23 10:11
Repligen price target raised to $208 from $180 at H.C. Wainwright
TipRanks · 03/23 10:11
REPLIGEN CORPORATION <RGEN.O>: H.C. WAINWRIGHT RAISES TARGET PRICE TO $208 FROM $180
Reuters · 03/23 10:09
More
Webull provides a variety of real-time RGEN stock news. You can receive the latest news about Repligen through multiple platforms. This information may help you make smarter investment decisions.
About RGEN
Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems. Its franchises include filtration, chromatography, process analytics and proteins. Its filtration franchise includes product offering covering upstream and downstream technologies. Its filtration products include XCell Alternating Tangential Flow (ATF) Cell Retention Systems, Flat Sheet Cassettes, Hollow Fiber Consumables, Tangential Flow Filtration Systems and Fluid Management. Its chromatography franchise includes products used in downstream purification, development, manufacturing and quality control of biological drugs. Its chromatography franchise includes OPUS Pre-Packed Columns, KRM Chromatography Systems and other additional chromatography products. Its process analytics include Downstream process analytical technology (PAT) and Upstream PAT. Its Proteins include Protein A Affinity Ligands, AVIPure Resins for New Modalities and Growth Factors.